Cancer Vaccines in Ovarian Cancer: How Can We Improve?

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2017 May 25

PMID 28536377

Citations 31

Authors

Silvia Martin Lluesma

Anita Wolfer

Alexandre Harari

Lana E Kandalaft

Affiliations

Soon will be listed here.

Abstract

Epithelial ovarian cancer (EOC) is one important cause of gynecologic cancer-related death. Currently, the mainstay of ovarian cancer treatment consists of cytoreductive surgery and platinum-based chemotherapy (introduced 30 years ago) but, as the disease is usually diagnosed at an advanced stage, its prognosis remains very poor. Clearly, there is a critical need for new treatment options, and immunotherapy is one attractive alternative. Prophylactic vaccines for prevention of infectious diseases have led to major achievements, yet therapeutic cancer vaccines have shown consistently low efficacy in the past. However, as they are associated with minimal side effects or invasive procedures, efforts directed to improve their efficacy are being deployed, with Dendritic Cell (DC) vaccination strategies standing as one of the more promising options. On the other hand, recent advances in our understanding of immunological mechanisms have led to the development of successful strategies for the treatment of different cancers, such as immune checkpoint blockade strategies. Combining these strategies with DC vaccination approaches and introducing novel combinatorial designs must also be considered and evaluated. In this review, we will analyze past vaccination methods used in ovarian cancer, and we will provide different suggestions aiming to improve their efficacy in future trials.

Citing Articles

Unlocking ovarian cancer heterogeneity: advancing immunotherapy through single-cell transcriptomics.

Balan D, Kampan N, Plebanski M, Abd Aziz N Front Oncol. 2024; 14:1388663.

PMID: 38873253 PMC: 11169633. DOI: 10.3389/fonc.2024.1388663.

Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial.

Dorigo O, Oza A, Pejovic T, Ghatage P, Ghamande S, Provencher D Clin Cancer Res. 2023; 29(15):2808-2815.

PMID: 37126016 PMC: 10390884. DOI: 10.1158/1078-0432.CCR-22-2595.

The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.

Wallis B, Bowman K, Lu P, Lim C Biomolecules. 2023; 13(1).

PMID: 36671544 PMC: 9855757. DOI: 10.3390/biom13010159.

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.

Revythis A, Limbu A, Mikropoulos C, Ghose A, Sanchez E, Sheriff M Int J Environ Res Public Health. 2022; 19(14).

PMID: 35886427 PMC: 9317199. DOI: 10.3390/ijerph19148577.

ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?.

Clemen R, Bekeschus S Vaccines (Basel). 2021; 9(5).

PMID: 34069708 PMC: 8161309. DOI: 10.3390/vaccines9050527.

References

Dalziel M, Crispin M, Scanlan C, Zitzmann N, Dwek R . Emerging principles for the therapeutic exploitation of glycosylation. Science. 2014; 343(6166):1235681. DOI: 10.1126/science.1235681. View

Derhovanessian E, Solana R, Larbi A, Pawelec G . Immunity, ageing and cancer. Immun Ageing. 2008; 5:11. PMC: 2564902. DOI: 10.1186/1742-4933-5-11. View

Chu C, Boyer J, Jawad A, McDonald K, Rogers W, Luning Prak E . Immunologic consequences of chemotherapy for ovarian cancer: impaired responses to the influenza vaccine. Vaccine. 2013; 31(46):5435-42. PMC: 3826173. DOI: 10.1016/j.vaccine.2013.09.001. View

Hakomori S . Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol. 2003; 491:369-402. DOI: 10.1007/978-1-4615-1267-7_24. View

Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A . Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol. 2014; 25(1):54-64. PMC: 4640687. DOI: 10.1016/j.semradonc.2014.07.003. View

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Mellman I, Steinman R . Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001; 106(3):255-8. DOI: 10.1016/s0092-8674(01)00449-4. View

Curran M, Montalvo W, Yagita H, Allison J . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9):4275-80. PMC: 2840093. DOI: 10.1073/pnas.0915174107. View

Melero I, Berman D, Aznar M, Korman A, Perez Gracia J, Haanen J . Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015; 15(8):457-72. DOI: 10.1038/nrc3973. View

10.

Kawamura Y, Toyota M, Kawashima R, Hagiwara T, Suzuki H, Imai K . DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology. 2008; 135(1):142-151.e3. DOI: 10.1053/j.gastro.2008.03.031. View

11.

Bapsy P, Sharan B, Kumar C, Das R, Rangarajan B, Jain M . Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Cytotherapy. 2014; 16(2):234-44. DOI: 10.1016/j.jcyt.2013.11.013. View

12.

Kooi S, Zhang H, Patenia R, Edwards C, Platsoucas C, Freedman R . HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol. 1996; 174(2):116-28. DOI: 10.1006/cimm.1996.0301. View

13.

Leffers N, Vermeij R, Hoogeboom B, Schulze U, Wolf R, Hamming I . Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int J Cancer. 2011; 130(1):105-12. DOI: 10.1002/ijc.25980. View

14.

Wolf D, Wolf A, Rumpold H, Fiegl H, Zeimet A, Muller-Holzner E . The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005; 11(23):8326-31. DOI: 10.1158/1078-0432.CCR-05-1244. View

15.

Schlienger K, Chu C, Woo E, Rivers P, Toll A, Hudson B . TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res. 2003; 9(4):1517-27. View

16.

Federici M, Kudryashov V, Saigo P, Finstad C, LLOYD K . Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression. Int J Cancer. 1999; 81(2):193-8. DOI: 10.1002/(sici)1097-0215(19990412)81:2<193::aid-ijc5>3.0.co;2-s. View

17.

Zhang S, Choi I, Huang J, Yoo J, Choi K, Yun C . Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther. 2011; 19(8):1558-68. PMC: 3149171. DOI: 10.1038/mt.2011.29. View

18.

Gnjatic S, Ritter E, Buchler M, Giese N, Brors B, Frei C . Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A. 2010; 107(11):5088-93. PMC: 2841879. DOI: 10.1073/pnas.0914213107. View

19.

Vanpouille-Box C, Pilones K, Wennerberg E, Formenti S, Demaria S . In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine. 2015; 33(51):7415-7422. PMC: 4684480. DOI: 10.1016/j.vaccine.2015.05.105. View

20.

Lesterhuis W, de Vries I, Aarntzen E, de Boer A, Scharenborg N, van de Rakt M . A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer. 2010; 103(9):1415-21. PMC: 2990614. DOI: 10.1038/sj.bjc.6605935. View